Advertisement
Mr. Sadowski brings 11 years experience in the Clinical Research sectorand a proven track record in rapidly creating new functional groups, businessunits and technical architectures from the ground up. He joins NewCardio fromeResearchTechnology (eRT), where he most recently served on the ExecutiveManagement Team as Senior VP of eRT's new Electronic Patient Reported Outcomes(ePRO) business unit while retaining responsibilities as the company's seniorexecutive for the Information Technology and Customer Care groups. Mr.Sadowski will be responsible for effectively preparing, delivering andsupporting the NewCardio cardiovascular diagnostic technology solutions, toinclude the Professional Services, Information Technology, Customer Care andQuality Assurance groups.
Advertisement
Mrs. Walsh also joins NewCardio from eRT, bringing over 11 years ofCorelab Management experience. As Vice-President, Project Management she wasresponsible for leading the Global Project Management department, the OnlineReporting Services department and the Training Academy department. She wasspecifically responsible for developing, implementing and streamliningprocesses to maximize revenue while maintaining and enhancing clientsatisfaction. At NewCardio, Mrs. Walsh will be responsible for ProductManagement, working with both internal and external teams to effectivelydefine and deliver the strategic cardiovascular diagnostic technologysolutions that will be derived from the NewCardio 3Dimensional platformtechnology.
Mr. Molina is a proven IT manager with nine years experience working atdiverse, fast-paced and rapidly-growing organizations. He brings a trackrecord of working with diverse groups and managing complex, mission-criticalprojects. Most recently, he served as Manager, Information Technology where heoversaw IT Operations at eRT's headquarters. At NewCardio he will beresponsible for developing and supporting the IT infrastructure, to includehardware, networks and corporate systems, required to support the strategicgrowth initiatives of the company.
Vincent Renz, NewCardio's President, commented, "I have worked closelywith each of these three professionals and as such, have great respect fortheir capabilities and expertise in working together as a team to bringquality solutions to market. I'm excited to have them join NewCardio,providing a solid foundation for building a world class Client Servicesorganization focused on working together for our customers. This represents amilestone event for NewCardio, as not only will this team prove instrumentalin accelerating our commercialization efforts, but will also send a clearsignal to our potential customers across the life sciences and health careindustries of our commitment to providing stellar service and compellingvalue."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on thedevelopment of a proprietary platform technology to provide higher accuracyto, and increase the value of, the standard 12-lead electrocardiogram (ECG).NewCardio's development-stage software and hardware products and services areintended to improve the diagnosis and monitoring of cardiovascular disease(CVD), as well as cardiac safety assessment of drugs under development.NewCardio's three-dimensional ECG platform is designed to reduce the time andexpense involved in assessing cardiac status while increasing the ability todiagnose clinically significant conditions which were previously difficult todetect. For more information, visit http://www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-lookingstatements include, but are not limited to, statements that express ourintentions, beliefs, expectations, strategies, predictions or any otherstatements relating to our future activities or other future events orconditions. These statements are based on current expectations, estimates andprojections about our business based on currently available information andassumptions made by management. Although we believe that the assumptions onwhich the forward-looking statements contained herein are based arereasonable, any of those assumptions could prove to be inaccurate given theinherent uncertainties as to the occurrence or nonoccurrence of future events.These statements are not guarantees of future performance and involve risksand uncertainties that are difficult to predict. Therefore, actual outcomesand results may, and are likely to, differ materially from what is expressedor forecasted in the forward-looking statements due to numerous factors,including the potential risks and uncertainties set forth in Item 1A of ourAnnual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 andrelate to our business plan, our business strategy, development of ourproprietary technology platform and our products, timing of such development,timing and results of clinical trials, level and timing of FDA regulatoryclearance or review, market acceptance of our products, protection of ourintellectual property, implementation of our strategic, operating and peopleinitiatives, benefits to be derived from personnel and directors, ability tocommercialize our products, our assumptions regarding cash flow fromoperations and cash on-hand, the amount and timing of operating costs andcapital expenditures relating to the expansion of our business, operations andinfrastructure, implementation of marketing programs, our key agreements andstrategic alliances, our ability to obtain additional capital as, and when,needed, and on acceptable terms and general economic conditions specific toour industry, any of which could impact sales, costs and expenses and/orplanned strategies and timing. We assume no obligation to, and do notcurrently intend to, update these forward-looking statements.
To join our email distribution please click this link:http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
SOURCE NewCardio, Inc.
